Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
Oculis (Nasdaq: OCS) and EURETINA have announced Dr. Prithvi Ramtohul as the winner of the 2025 Ramin Tadayoni Award, which honors exceptional postgraduate scholars in retina research. The award, established in 2024, commemorates Professor Ramin Tadayoni, Oculis' former Chief Scientific Officer.
Dr. Ramtohul, an attending physician at Aix-Marseille University Hospital and Ph.D. candidate, is recognized for his contributions to retinal imaging and diseases, with 111 peer-reviewed publications. His research focuses on cellular mechanisms of amblyopia and retinal disease pathophysiology through multimodal imaging analysis.
Oculis (Nasdaq: OCS) e EURETINA hanno annunciato il dott. Prithvi Ramtohul come vincitore del Ramin Tadayoni Award 2025, riconoscimento destinato a laureati eccezionali nella ricerca sulla retina. Il premio, istituito nel 2024, 猫 dedicato alla memoria del professor Ramin Tadayoni, ex Chief Scientific Officer di Oculis.
Il dott. Ramtohul, medico dirigente presso l'ospedale universitario Aix-Marseille e dottorando, 猫 stato premiato per i suoi contributi nell鈥檃mbito dell鈥檌maging retinico e delle malattie retiniche, con 111 pubblicazioni peer-reviewed. I suoi studi si concentrano sui meccanismi cellulari dell鈥檃mbliopia e sulla patofisiologia delle malattie retiniche mediante analisi multimodale delle immagini.
Oculis (Nasdaq: OCS) y EURETINA han anunciado al Dr. Prithvi Ramtohul como ganador del Premio Ramin Tadayoni 2025, que reconoce a destacados investigadores posgraduados en retina. El galard贸n, creado en 2024, rinde homenaje al profesor Ramin Tadayoni, ex Director Cient铆fico de Oculis.
El Dr. Ramtohul, m茅dico adjunto en el Hospital Universitario Aix-Marseille y candidato a doctorado, ha sido reconocido por sus aportes en imagen retiniana y enfermedades de la retina, con 111 publicaciones revisadas por pares. Su investigaci贸n se centra en los mecanismos celulares de la ambliop铆a y la fisiopatolog铆a de las enfermedades retinianas mediante an谩lisis multimodal de im谩genes.
Oculis (Nasdaq: OCS)鞕� EURETINA電� 2025 霛茧 韮�雼れ殧雼堨儊 靾橃儊鞛愲 頂勲Μ韸鸽箘 霝岉埇鞖� 氚曥偓毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 靸侅潃 毵濍 鞐瓣惮 攵勳暭鞚� 鞖办垬頃� 雽�頃欖洂 鞐瓣惮鞛愲ゼ 旮半Μ電� 靸侅瀰雼堧嫟. 2024雲勳棎 鞝滌爼霅� 鞚� 靸侅潃 Oculis鞚� 鞝� 靾橃劃瓿柬暀鞛� 霛茧 韮�雼れ殧雼� 甑愳垬毳� 旮半厫頃╇媹雼�.
霝岉埇鞖� 氚曥偓電� 鞐戩姢毵堧ゴ靹胳湢 雽�頃欕硲鞗� 靻岇啀 欤检箻鞚橃澊鞛� 氚曥偓瓿检爼 鞐瓣惮鞛愲, 毵濍 鞓侅儊 氚� 毵濍 歆堩櫂 攵勳暭鞐� 旮办棳頃� 瓿惦搿� 鞚胳爼氚涭晿鞙茧┌ 霃欕鞁偓 雲茧 111韼�鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 攴胳潣 鞐瓣惮電� 雼れ氇嫭 鞓侅儊 攵勳劃鞚� 韱淀暣 鞎届嫓鞚� 靹疙彫旮办爠瓿� 毵濍 歆堩櫂鞚� 氤戫儨靸濍Μ毳� 攴滊獏頃橂姅 雿� 齑堨爯鞚� 毵烄稊瓿� 鞛堨姷雼堧嫟.
Oculis (Nasdaq: OCS) et EURETINA ont annonc茅 le Dr Prithvi Ramtohul comme laur茅at du Ramin Tadayoni Award 2025, qui r茅compense d鈥檈xcellents chercheurs postgradu茅s en imagerie r茅tinienne. Cr茅茅 en 2024, ce prix rend hommage au professeur Ramin Tadayoni, ancien Chief Scientific Officer d鈥橭culis.
Le Dr Ramtohul, m茅decin hospitalier 脿 l鈥橴niversit茅 Aix-Marseille et doctorant, est reconnu pour ses apports en imagerie r茅tinienne et dans le domaine des maladies de la r茅tine, avec 111 publications 茅valu茅es par des pairs. Ses travaux portent sur les m茅canismes cellulaires de l鈥檃mblyopie et la physiopathologie des maladies r茅tiniennes via l鈥檃nalyse multimodale d鈥檌mages.
Oculis (Nasdaq: OCS) und EURETINA haben Dr. Prithvi Ramtohul als Preistr盲ger des Ramin Tadayoni Award 2025 bekanntgegeben 鈥� eine Auszeichnung f眉r herausragende Postgraduierten-Forscher im Bereich der Netzhaut. Der 2024 eingerichtete Preis erinnert an Professor Ramin Tadayoni, den ehemaligen Chief Scientific Officer von Oculis.
Dr. Ramtohul, Oberarzt am Universit盲tsklinikum Aix-Marseille und Doktorand, wird f眉r seine Beitr盲ge zur Netzhautbildgebung und zu Netzhauterkrankungen geehrt. Er verf眉gt 眉ber 111 von Experten begutachtete Publikationen. Seine Forschung konzentriert sich auf zellul盲re Mechanismen der Amblyopie und die Pathophysiologie retinaler Erkrankungen mittels multimodaler Bildanalyse.
- None.
- None.
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (鈥淥culis鈥�), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs,听today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025.
The Ramin Tadayoni Award honors the next generation of ophthalmologists by supporting an exceptional postgraduate scholar in retina research. It was established in 2024 in memory of the late Professor Ramin Tadayoni, Oculis鈥� former Chief Scientific Officer and a globally renowned leader in retinal science.
This year鈥檚 award recognizes Prithvi Ramtohul, M.D., for his significant contributions to the field of retinal imaging and diseases, and he is currently studying the long-lasting plasticity of intrinsic neuronal excitability in retinal ganglion cells.
Anat Loewenstein, M.D., President of EURETINA, said: 鈥淥n behalf of EURETINA, I would like to express my gratitude to all the applicants. The standard and scope of entries submitted were remarkable, and we are delighted to recognize Dr. Ramtohul as our 2025 award recipient, who carries forward this honorable tribute. With his retinal research project, Dr. Ramtohul aims to advance our understanding of the cellular mechanisms underlying amblyopia and inform the development of targeted therapeutic interventions to improve patient outcomes. I would like to sincerely thank the review committee members and all parties involved for their contribution to this award.鈥�
Riad Sherif, M.D., Chief Executive Officer of Oculis, said: 鈥�It is our privilege to collaborate with EURETINA on the Ramin Tadayoni Award, and we extend our congratulations to our distinguished 2025 winner, Dr. Ramtohul. Through our ongoing commitment to this award and dedication to excellence in retinal research, we continue to celebrate the remarkable legacy of Professor Ramin Tadayoni, whom we deeply valued as both a friend and colleague."
Dr. Prithvi Ramtohul is an attending physician in the Retinal Division at Aix-Marseille University Hospital, North, France, and a Ph.D. candidate at the Ion Channel and Synapse Neurobiology Unit, INSERM-AMU, Marseille, France. Following his ophthalmology residency at Aix-Marseille University and fellowship training with Professor Ramin Tadayoni at Hospital Lariboisi猫re, Paris, he completed a prestigious research fellowship with Professor K. Bailey Freund at the Vitreous Retina Macula Consultants of New York. Dr. Ramtohul has made significant contributions to retinal imaging and diseases through his 111 peer-reviewed publications, particularly as first author on groundbreaking studies describing novel OCT signs such as bacillary layer detachment (BALAD) and the angular sign of Henle fiber layer hyperreflectivity (ASHH), as well as newly identified retinal conditions including Stellate Multiform Amelanotic Choroidopathy (SMACH) and Multizonal Outer Retinopathy and Retinal Pigment Epitheliopathy (MORR). His research focuses on enhancing the understanding of retinal disease pathophysiology through the analysis of multimodal imaging. His contributions have been recognized with prestigious awards, including the Gabriel Coscas Award from the French Retina Society, as well as invitations to speak at 73 national and international conferences.
-ENDS-
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis鈥� highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNF伪 in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit:听
Oculis Contacts
Ms. Sylvia Cheung, CFO
听
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
听
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
FAQ
Who won the Ramin Tadayoni Award 2025 from Oculis (OCS)?
What is the Ramin Tadayoni Award established by Oculis (OCS)?
What are Dr. Ramtohul's main research contributions recognized by Oculis (OCS)?
Where does the 2025 Oculis (OCS) award winner Dr. Ramtohul work?
